FDA Rejects Mallinckrodt's Abuse-Deterrent Roxicodone Reformulation
The FDA issued a Complete Response Letter for SpecGx LLC's abuse-deterrent, immediate-release reformulation of Roxicodone (oxycodone hydrochloride) tablets.
Β© Copyright 2025. All Rights Reserved by MedPath